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1. Introduction 
Genetic susceptibility seems to play an important role in some gastric cancers. In some rare 
cases, gastric cancer can be one part of familial cancer syndromes. A well-known example is 
the family of Napoleon since the Emperor himself as well as his father and his grandfather 
had gastric cancer. Generally, hereditary factors include germline mutations of E-cadherin, 
APC, p53 or mismatch repair genes like hMLH1 or hMSH2. Gatekeeper genes like E-
cadherin and APC encode signaling proteins important to cellular proliferation and 
differentiation while protein products from caretaker genes like p53 or mismatch repair 
genes are important to maintain the integrality and fidelity of the genome. In addition to 
gene mutations, gene polymorphisms have been shown to be associated with the 
susceptibility of gastric cancer (El-Omar et al., 2000; Persson et al., 2011). Interestingly, most 
of these genes are encoding proinflammatory cytokines, strongly indicating the importance 
of inflammation to the initiation and progression of gastric cancer.  
Environment factors play important roles in the pathogenesis of gastric cancer by affecting 
the inflammation in the stomach. The infection of Helicobacter pylori is apparently one of 
the primary risk factors of gastric cancer. In 1994, the World Health Organization and the 
International Agency for Research on Cancer Consensus group classified H. pylori as a type 
I carcinogen in human beings. Although numerous studies reported the growth promoting 
effect of H. pylori or its derived proteins in vitro, no direct evidence about the interaction of 
H. pylori with cancer initiating or stem cells have been presented. In contrast, accumulating 
reports indicated that the inflammation induced by H. pylori infection is the key to gastric 
carcinogenesis. Thus, it was believed that H. pylori infection is the initial step in the 
stepwise process of gastric carcinogenesis starting from chronic gastritis, gastric atrophy, 
intestinal metaplasia, dysplasia to gastric carcinoma. Consistently, diets rich in fruit and 
vegetables is protective factors of gastric cancer since vitamin C are helpful to attenuate 
inflammation while inflammation-promoting factors such as smoking, foods with high salts 
and nitrite could facilitate the development of gastric cancer by promoting chronic 
inflammation.  
Microenvironments in chronic inflammatory tissues are rich in growth factors and cytokines 
important to promote the perpetuation of tumor growth by epigenetically reprogramming 
cancer stem cells. In addition, there are some DNA damage inducing agents such as reactive 
oxygen and nitrogen species (RONS) that can cause genomic alterations, promoting the 
accumulation of mutations in proliferating cancer stem cells (Meira et al., 2008). On the other 
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hand, cancer cells during their progression can not only circumvent inhibitory signals from 
immune cells in inflammatory microenvironments but also suppress the anti-tumor immune 
response, eventually transforming the inflammation microenvironment into tumor 
permissive microenvironment, the niche for the survival and expansion of cancer stem cells 
(Wang and Jin, 2010). 
Tumor promoting factors in tumor-permissive microenvironments can reprogram 
epigenetic regulatory network in cancer cells through various signaling pathways that 
deregulated in both inflammation and carcinogenesis, such as NF-kB pathway and IL6-
STAT3 pathway (Pikarsky et al., 2004; Yu et al., 2009a). However, epigenetic changes 
directly controlled by intracellular signaling pathways can immediately reform cellular 
response to extracellular signals and therefore most likely precede genetic changes that take 
several cell divisions to be fixed. Similar to genetic changes, epigenetic changes can also 
affect the activity of many signaling pathways critical to cancer development. By doing so, 
epigenetic trans-generation of extracellular signals plays important roles in the initiation of 
many sporadic cancers (Figure 1).  
 
 
Fig. 1. Gastric cancer is resulting from the accumulation of genetic and epigenetic changes. 
Genetic factors such as polymorphism of genes encoding cytokines affect the pathogenesis 
of inflammation induced by environmental factors such as H. Pylori infection. Bioactive 
factors enriched in inflammatory microenvironments such as IL-6, INF-α and other 
prosurvival and anti-apoptotic signals could reprogram epigenetic regulatory network to 
promote genetic changes and the subsequent malignant transformation of stem or 
progenitor cells. The interaction of transformed stem cells with microenvironment gradually 
transformed microenvironment into tumor permissive microenvironment and stem cells 
into cancer stem cells.  
2. Epigenetic view of gastric carcinogenesis 
Epigenetic information is defined as cellular information heritable during cell division in 
addition to DNA sequence. Epigenetic network regulates the expression or function but not 
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the sequence of genes. Up to date, the major components of epigenetic regulatory network 
include DNA methylation, non-coding RNAs mainly microRNAs and histone modifications. 
Similar to genetic changes, some of epigenetic changes are important to maintain the 
malignant phenotypes of cancer cells and thereby could be named as driver epigenetic 
changes while the others are passenger epigenetic changes since they are passively altered 
during cancer development.  
 
Mechanism Name Scale 
Bisulfite dependent MS-PCR Single Gene 
BGS Single Gene 
MDFS Single Gene 
Cobra Single Gene 
Bisulfite independent Enzyme digestion-Southern Blot Single Gene 
Enzyme digestion-PCR Single Gene 
RLGS Genome wide 
aPRIMES Genome wide 
MB-PCR Single Gene 
MB-Array/-sequencing Genome wide 
Table 1. Methods to detect DNA methylation 
3. Aberrant DNA methylation in gastric carcinogenesis 
DNA methylation is a type of chemical modification with the covalent addition of a methyl 
group to the fifth position of cytosine predominantly within the CpG dinucleotides. As one 
of the major mechanisms of epigenetic regulation, DNA methylation is involved in a 
number of important biological processes including linage-specific gene expression, parental 
or maternal imprinting and tumor suppressor gene silencing in carcinogenesis (Bird, 1986; 
Jones, 2002). Aberrant DNA methylation is deeply involved in gastric carcinogenesis by 
affecting various cellular processes including signal transduction, cell cycle regulation and 
gene expression. In addition to driver methylations, there are passenger methylations that 
could be used as the biomarkers for the detection or monitoring of cancer development and 
progression instead of the screening or defining of novel tumor suppressor genes. The genes 
silenced by DNA methylation in gastric cancer have been intensively discussed and thus 
will not be included here (Choi and Wu, 2005; Tamura, 2006). Instead, the potential 
application of DNA methylation in the detection of gastric cancer will be overviewed after 
the brief introduction of general approaches to detect DNA methylation. 
3.1 General approaches to detect DNA methylation  
In general, the approaches to detect DNA methylation could be grouped into two classes: 
bisulfite-dependent methods and bisulfite-independent methods (Table 1). Methylated DNA 
could be differentiated from unmethylated DNA by bisulfite DNA modification or 
restriction enzyme digestion. Bisulfite treatment could change unmethylated cytosine into 
uracil while left methylated cytosine unchanged. DNAs with different methylation status 
respond to the digestion of methylation-sensitive restriction enzymes differently, making it 
possible to detect DNA methylation indirectly by analyzing the products of enzyme 
digestion.  
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After the conversion of unmethylated cytosine into uracil by bisulfite treatment, methylated 
DNA could be amplified by methylation specific-PCR (MS-PCR) with specifically designed 
primers (Herman et al., 1996). The advantage of this method includes the fast detection of 
DNA methylation with high sensitivity and specificity. The main disadvantage is the low 
level of resolution to determine the methylation of particular CpG sites only in the 3’-
terminus of primers. The pattern of multiple methylated CpG sites could be determined by 
bisulfite genome sequencing in which PCR products with methylation non-selective primers 
will be directly sequenced or sequenced indirectly after TA cloning. Alternatively, 
methylation could be quantified by MethyLight in which methylation or unmethylation 
specific probes were used in PCR amplification (Eads et al., 2000). Other quantitative 
methods include MS-HRM (Methylation-sensitive high resolution melting) which takes the 
advantage of the differences in melting of PCR products from methylated and unmethylated 
DNA while methylation-dependent fragment separation (MDFS) could detect DNA 
methylation by comparing differential migration times of PCR products in electrophoresis 
(Boyd et al., 2006; Wojdacz and Dobrovic, 2007). In the method termed Cobra (combined 
Bisulfite Restriction Analysis), PCR products from bisulfite-treated DNAs will be digested 
by restriction enzymes like BstUI and the resulting fraction could directly reflect the 
percentage of methylated and unchanged CpGs at sites that will be cut by the enzymes. It is 
relatively sensitive and small amount of DNAs from tiny tissues could be used for Cobra 
analysis (Xiong and Laird, 1997). However, it is semi-quantitative and restricted to analyze 
CpGs only in special sites of particular restriction enzymes. Overall, the efficiency of 
bisulfite conversion which is a complicated and time consuming procedure with relatively 
low sensitivity and high false positive rate is the critical factor for bisulfite dependent 
approaches to quantify DNA methylation. 
In bisulfite independent groups, methylated DNAs are differentiated from unmethylated 
DNA by either enzyme digestion or affinity enrichment. In contrast to other quantification 
methods like MSP, enzyme digestion based methods could analyze the methylation pattern 
of multiple CpGs sites. The resulting products from methylation-sensitive restriction 
enzymes could be further analyzed by Souther blot or PCR at the single gene level and 
RLGS (restriction landmark genomic scanning) or aPRIMES (array based profiling of 
reference independent methylation status) in genome-wide level to screening novel 
methylated sites. The influence of digestion efficiency could be adjusted by the internal 
control which could not be cut by the particular enzyme irrespective of DNA methylation. 
Methylated DNA could also be analyzed by PCR, sequencing or array based hybridization 
after being enriched by anti-5-methylcytosine antibody or methylation binding domain 
(MBD) containing proteins. It could yield the information including both the level and 
pattern of DNA methylation with physiological relevance.  
3.2 DNA methylation as biomarkers for gastric cancer 
Although there are many studies reporting that methylation of particular genes could be 
useful to predict the prognosis of gastric cancer, few of them were validated to be superior 
to classical prognosis prediction factors such as TNM staging (Liu et al., 2010; Yu et al., 
2009b). Therefore, the clinical application of DNA methylation in prognosis predication of 
gastric cancer remains uncertain. In contrast, the detection of methylated DNA markers is 
believed to be useful to detect newly and relapsed gastric cancer, thus representing a 
promising approach of developing non-invasive detection for gastric cancer progression 
(Corvalan and Maturana, 2010; Laird, 2003).  
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Biomarker detection in peritoneal fluid is clinically important and feasible to determine the 
micrometastesis to the peritoneum of gastric cancer which is the most frequent event in 
recurrent gastric cancer and often associated with resistance to chemotherapy and poor 
prognosis. The detection of peritoneal micrometastasis is critical for patients to take timely 
and correct treatment based on an accurate diagnosis. Based on the quantitatively detection 
of methylated DNAs with the MethyLight method, DNA methylation in peritoneal fluids 
was found to be able to detect occult neoplastic cells in the peritoneum (Hiraki et al., 2011; 
Hiraki et al., 2010). Among 11 genes reported to be methylated in gastric cancer, BNIP3, 
CHFR, CYP1B1, MINT25, SFRP2, and RASSF2 were specifically methylated in tumor tissues 
but not adjacent non-tumor tissues. Interestingly, the methylation status of all six genes 
were significantly different among three different groups: patients with tumor invasion 
under muscularis propria (MP) (n=42, methylation percentage: 0-5%), patients with tumor 
invasion beyond the MP (n=45, methylation percentage: 0-15%) and patients with 
histologically or cytologically confirmed peritoneal metastasis (n = 20, methylation 
percentage: 15-45%). Among 45 patients with tumor invasion beyond the MP, 3 of 9 patients 
with methylation in any of 6 genes were diagnosed as peritoneal recurrence later while only 
1 out of 35 patients without methylation in any of 6 genes developed peritoneal metastasis 
at least 8 months after surgery (Hiraki et al., 2011). Other potential methylation markers of 
peritoneal metastasis of gastric cancer include RUNX3 which was silenced by DNA 
methylation in 100% of peritoneal metastases of gastric cancers and 75% of primary gastric 
cancers but not normal gastric mucosa (Sakakura et al., 2005).  
In addition to detect methylated DNA in peritoneal fluids, researchers have endeavored to 
develop sensitive methods to quantify methylated DNA in peripheral bloods. It is 
promising to identify sensitive circulating biomarkers to detect early gastric cancer at a 
curable stage.  
In a qualitative analysis of methylated p16, E-cadherin, and retinoic acid receptor-1 
(RARbeta) in serum, 52 patients (48%) of the 109 preoperative gastric cancer patients 
showed hypermethylation of at least one gene while no methylation of any of three genes 
was detected in control sera (Ikoma et al., 2007). Furthermore, methylation of three genes 
was detected in 2 of the 3 patients with recurrence, indicating that the detection of the 
methylated DNA in circulation could facilitate the early detection of newly and recurrent 
gastric cancer. The methylations of p16, Reprimo as well as RASSF1A were also proposed as 
potential biomarkers for early detection of gastric cancer (Abbaszadegan et al., 2008; Bernal 
et al., 2008; Wang et al., 2008). 
The quantitative analysis of RUNX3 methylation in serum revealed that methylated RUNX3 
was detected in 29% (19/65) of gastric cancer patients and the serum level of methylated 
RUNX3 was concordant with tumor burden as well as disease stage, histology, lymphatic 
and vascular invasion (Sakakura et al., 2009). In addition, it seems to be more sensitive than 
serum level of carcinoembryonic antigen (CEA) as a biomarker for the detection of gastric 
cancer. However, the methylation of RUNX3 is not specific to gastric cancer and methylated 
RUNX3 could be detected in patients with various cancers such as breast cancer and lung 
cancer, indicating that methylation of RUNX3 could be more useful in monitoring the 
progression or recurrence of gastric cancer than in screening asymptomatic patients with 
early gastric cancer (Tan et al., 2007). Similarly, preferential methylation in the serum DNA 
of gastric cancer patients was noted in APC (17%), E-cadherin (13%), hMLH1 (41%) and 
TIMP3 (17%) genes and patients with advanced gastric cancer tended to have higher 
www.intechopen.com
 
Gastric Carcinoma - Molecular Aspects and Current Advances 
 
60
concentrations of methylated APC, TIMP3 and hMLH1 in the serum (Leung et al., 2005). 
Overall, methylations in at least one of these markers were detected in the serum of 33 
patients (55%) while no methylation was detected in normal subjects. The combined use of 
APC and E-cadherin methylation markers identified a subgroup of gastric cancer patients 
with worse prognosis (Leung et al., 2005). 
Similar to diver mutations, methylations in critical or driver genes are most likely not 
specific to gastric cancer. The value of driver methylation in the screening of gastric cancer is 
certainly controversial. Most of potential biomarkers, however, are usually transformed 
from functional studies. Many passenger methylations were, thus, discarded for further 
validation of their potential as indicators of gastric cancer development. Many biomarkers 
currently used in clinic, such as AFP, CEA and CA-125, are not functional oncogenes or 
tumor suppressors per se. To identify biomarkers for clinical application, more attention 
should be paid to those passenger methylations instead of driver methylations although 
they are probably not important to the development or progression of gastric cancer in 
function. In addition, quantitative MSP is currently the most often used approach to detect 
DNA methylated in blood. It would be more interesting to see the progress on the 
biomarkers identified by methods based on affinity enrichment since methylation contents 
with physiological relevance instead of single or few methylated sites could be determined. 
4. MicroRNAs deregulated in gastric carcinogenesis 
Although there are some discrepancies in the microRNA profiling of cell lines and primary 
tissues, microRNAome as a whole is downregulated in human carcinogenesis. It was 
believed that the general downregulation of microRNAs in cancer cells is mainly caused by 
the impaired post-transcriptional maturation of microRNAs starting from primary 
microRNA transcripts rather than the transcriptional of microRNA genes (Croce, 2009; Lee 
et al., 2008; Slezak-Prochazka et al., 2010; Thomson et al., 2006; White et al., 2005; Winter et 
al., 2009). The functions of microprocessors necessary and sufficient for processing 
microRNA precursors are generally suppressed in cancer cells partially due to the reduced 
expression of Drosha and Dicer, two major enzymes responsible for the maturation of 
microRNAs (Dedes et al., 2011; Hwang et al., 2009; Karube et al., 2005; Lee et al., 2008; Lin et 
al., 2010; Merritt et al., 2008). In addition, proteins with tumor suppressing functions like 
p53 were found to participate in the maturation of microRNAs (Bikkavilli and Malbon, 2010; 
Davis et al., 2008; Suzuki et al., 2009). 
In contrast to genome-wide downregulation of microRNAs, some microRNAs are 
specifically upregulated in cancer cells. MicroRNAs have been implicated in the control of 
many fundamental cellular and physiological processes such as cellular differentiation and 
proliferation, stem cell maintenance and tissue development. By acting as oncogenes or 
tumor suppressors, microRNAs also play a significant role in cellular transformation and 
carcinogenesis (Inui et al., 2010; Wiemer, 2007; Wu et al., 2010). In the next, we will briefly 
overview the very recent studies on the relevance of microRNAs deregulated in gastric 
carcinogenesis to signal transduction, cell cycle and apoptosis control, and transcriptional 
regulation.  
4.1 MicroRNAs in signal transduction 
MiR-204 and probably miR-211 are downregulated in gastric cancer, contributing to the 
aberrant Ras activation by inhibiting the expression of ezrin (Lam et al., 2011). As a 
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membrane-cytoskeleton linker protein, ezrin can promote Ras activation by stimulating the 
assembly of SOS-Ras complex (Morrison et al., 2007). Therefore, downregulation of miR-204 
in gastric cancer represents a new mechanism of aberrant Ras activation which was often 
attributed to Ras mutations in many other cancers. CDC42, one Ras-related small G protein 
that plays important roles in the regulation of cell motility and tumor metastasis, was found 
to be targeted by miR-137 in gastric cancer cells (Chen et al., 2011). MiR-137 was 
downregulated in many cancers including gastric cancer probably due to the 
hypermethylation of its promoter. As the upstream regulator of MAPK signaling, EGF 
receptor ERBB2 was found as the direct target of miR-125a-5p (Nishida et al., 2011). While 
miR-125a-5p could potently suppress the proliferation of gastric cancer cells, low expression 
levels of miR-125a-5p were associated with enhanced malignant potential such as tumor 
size, tumor invasion and liver metastasis. By blocking apoptosis and promoting cell 
survival, NF-kappaB pathway plays important roles in both inflammation and cancer and is 
often activated in gastric carcinogenesis. NF-kappaB1 is directly targeted by miR-9 which 
was downregulated in gastric carcinomas (Wan et al., 2010). MiR-516a-3p can block 
metastatic dissemination of gastric cancer cells and was downregulated in highly metastatic 
gastric carcinoma cells. It can suppress the expression of sulfatase 1 which is known to 
promote the activation of wnt/beta-catenin signaling pathway by removing 6-O-sulfates 
from heparan sulfate proteoglycans on the cell surface and causing the release of membrane-
bound wnt ligands from plasma membrane (Takei et al., 2011). The G-protein coupled 
receptor of gastrin, cholecystokinin B receptor (CCKBR), is regulated by miR-148b which 
was downregulated in gastric cancer (Song et al., 2011). Restored expression of miR-148b in 
gastric cancer cells inhibited cell growth both in vitro and in vivo.  
4.2 MicroRNAs in cell cycle and apoptosis control 
Cell cycle checkpoints consist of many proteins including cyclins, cyclin dependent kinases 
(CDKs) and CDK inhibitors (CKIs) to secure the integrity and fidelity of genome during cell 
mitosis. It was found that members of same family of CKIs could be regulated by 
microRNAs in one cluster. For example, miR-25 targeted p57 (Kip2) and the other two 
microRNAs in this cluster suppressed the expression of p21 (Cip1); while miR-222 and miR-
221 cluster regulated both p27 (Kip1) and p57 (Kim et al., 2009). MicroRNAs in one cluster 
usually display similar pattern of expression, therefore ensuring the effect to attenuate the 
function of targeted proteins by interacting with different regions in 3’-UTR of the same 
gene. Cyclin G1 was targeted by miR-122 which was downregulated in gastric cancer and 
colorectal cancer probably due to aberrant activation of wnt signaling (Fornari et al., 2009; 
Wang et al., 2009).  
As a direct target of p53, miR-34 was downregulated in gastric cancer. MiR-34 could inhibit 
the growth of gastric cancer cells by targeting anti-apoptotic oncoprotein Bcl-2 (Ji et al., 
2008). Bcl-2 was also targeted by miR-181b, which was downregulated in multidrug-
resistant human gastric cancer cell line SGC7901/vincristine (VCR). Enforced miR-181b 
expression reduced Bcl-2 protein level and sensitized SGC7901/VCR to VCR-induced 
apoptosis (Zhu et al., 2010). The novel tumor suppressor protein programmed cell death 4 
(PDCD4) was downregulated in several human solid cancer types. PDCD4 was the target of 
miR-21 which was upregulated in gastric cancer in response to the activation of NF-kB 
signaling by smoking and many other factors such as inflammation (Motoyama et al., 2010).  
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4.3 MicroRNAs in transcription regulation 
SRY (sex-determining region Y)-box 2 (SOX2) is a crucial transcription factor for the 
maintenance of stem cell pluripotency and the determination of cell fate. Its expression was 
reduced in gastric cancer cells due to the upregulation of miR-126 (Otsubo et al., 2011). 
Enhanced expression of miR-126 significantly promoted both anchorage-dependent and -
independent growth of gastric cancer cells by reducing SOX2 expression. Similarly, SOX4 
was upregulated in gastric cancers compared with benign gastric tissues probably resulting 
from the epigenetic silencing of miR-129-2 (Shen et al., 2010). Restoration of miR-129-2 
induced apoptosis of gastric cancer cells.  
In addition to transcription factors that regulate gene expression through direct interaction 
with DNA, many other proteins especially in the epigenetic regulatory network are also 
targeted by microRNAs. As one component in the polycomb complex, EZH2 plays 
important roles in stem cell homeostasis as well as cancer development. It has been proven 
to be upregulated in many cancers including gastric cancer. Such an upregulation is at least 
partially caused by the downregulation of miR-101 (Varambally et al., 2008; Wang et al., 
2010). Restoration of miR-101 expression in gastric cancer cells led to the significant 
inhibition of cellular proliferation, migration and invasion as well as tumorigenicity. 
Another chromatin remodeling protein ING4 (Inhibitor of growth family, member 4) was 
targeted by miR-650 which was downregulated in gastric cancer and could promote 
tumorigenesis and proliferation of gastric cancer cells (Zhang et al., 2010). Methyl-CpG-
binding protein MeCP2 could promote cancer development by initiating the assembly of 
transcription inhibitory complex to silence the expression of tumor suppressors. It was 
found to be the direct target of miR-212 which was downregulated in gastric cancer (Wada 
et al., 2010). Transfection of the miR-212 precursor into gastric cancer cells induced 
significant decrease of cell growth in vitro. In addition to methylated DNA binding proteins 
and histone modification related proteins, DNA methyltransferases (DNMTs) were directly 
targeted by microRNAs as well (Ng et al., 2009b). MiR-143 was frequently downregulated in 
gastric cancer and many other cancers and one target directly regulated by miR-143 was 
turned out to be DNA methyltranserase-3A (DNMT-3A) (Takagi et al., 2009). The 
transcription of DNMT-3A was resulted from aberrant Ras activation. Therefore, 
downregulation of miR-143 could be in concert with Ras activation to promote 
carcinogenesis by increasing the expression of DNMTs to promote hypermethylation-
mediated silencing of tumor suppressors.  
4.4 Deregulated microRNAs as biomarkers for gastric cancer 
The number of microRNAs deregulated in gastric cancer is still increasing (Hou et al., 2011; 
Lee and Dutta, 2009; Wu et al., 2010). Many other microRNAs important to gastric 
carcinogenesis were not included due to the limitation of the space. For example, 
macrophage migration inhibitory factor (MIF) which plays important roles in the 
transformation of tumor-permissive microenvironment was targeted by miR-451 and miR-
451 was downregulated in gastric cancer. The downregulation of miR-451 was associated 
with worse prognosis and restoration of miR-451 expression in gastric cancer cells reduced 
cell proliferation and increased sensitivity to radiation (Bandres et al., 2009). Microsatellite 
instability (MSI) was believed to be one important feature of some gastric cancers. MSI was 
usually caused by the mutations in mismatch repair (MMR) genes or reduced expression of 
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MMRs. A microRNA contribution to MSI was recently identified. MiR-155 which was 
overexpressed in gastric cancers could target the expression of several MMR genes, such as 
hMSH2, hMSH6, and hMLH1 (Valeri et al., 2010). 
The clarification of their biological relevance will certainly deepen our understanding of 
carcinogenesis so that new and effective therapeutics could be developed. Different 
microRNAs could regulate gene expression by targeting different sites in the 3’-UTR of the 
same gene and a single microRNA could target more than one gene. Computational 
predictions indicate over 50% of human protein-coding genes might be regulated by 
microRNAs although there are only several hundred of microRNAs in human genome. In 
addition, microRNA could regulate gene expression by interacting with 5’-UTR even other 
elements in the gene, making it challenging to understand the biological relevance of 
microRNAs.  
Interestingly, microRNAs were also recognized as the next generation of biomarkers for the 
diagnosis and prognosis prediction of cancers due to the development of methods to 
quantify microRNA expression in both tissues and bloods. Realtime RT-PCR and in situ 
hybridization could detect the expression of microRNA in tissues quantitatively or semi-
quantitatively. Many studies have confirmed that microRNAs could be used for prognosis 
prediction (Iorio et al., 2008). For example, miR-125a-5p expression was found to be an 
independent prognostic factor and its lower expression in tumor tissues was often 
associated with shorter survival (Nishida et al., 2011). In a screening with a large cohort of 
353 gastric samples, miR-125b, miR-199a and miR-100 were found to be related with the 
progression of gastric cancer while the downregulation of let-7g and miR-433 and the 
upregulation of miR-214 were associated with unfavorable outcome in overall survival 
independent of clinical covariates, including depth of invasion, lymph-node metastasis, and 
stage (Ueda et al., 2010). Based on the study of a relative small scale cohort of 160 gastric 
cancer patients, a signature consisting of miR-10b, miR-21, miR-223, miR-338, let-7a, miR-
30a-5p and miR-126 was found as an independent predictor of overall survival and relapse-
free survival (Li et al., 2010). Six microRNAs including miR-103, miR-21, miR-145, miR-106b, 
miR-146a and miR-148a were screened out from a total of 857 microRNA probes to separate 
node-positive from node-negative gastric cancers, indicating that these six miRNAs may be 
useful for the decision-making of doctors by the prediction of potential lymph node 
metastasis (Tchernitsa et al., 2010). Other microRNAs such as miR-27a was also related with 
the lymph node metastasis of gastric cancer (Katada et al., 2009). However, no microRNA 
signature was commonly accepted to predict the prognosis of gastric cancer since results 
from different labs were usually different. This could be due to the different methods used 
in different labs. Alternatively, the ethnic variation could be one of the reasons. Large scale 
multi-centered clinical trials will be warranted to validate the relevance of microRNA based 
signature to the prognosis predication of gastric cancer. 
Given the stability in nature, microRNAs in peripheral blood or other body fluids were 
recognized as the ideal biomarkers for various cancers (Ng et al., 2009a). The plasma 
miRNA levels usually reflected the expression level of microRNAs in tumor tissues 
(Tsujiura et al., 2010). Microarray and new generations of sequencing platforms have been 
widely used to screen circulating microRNAs for the diagnosis of gastric cancer. Solexa 
sequencing of microRNAs in serum from 20 patients with gastric cancer and 20 age- and 
gender-matched tumour-free controls revealed 19 miRNAs specifically upregulated in 
gastric cancer. Five of them including miR-1, miR-20a, miR-27a, miR-34 and miR-423-5p 
were confirmed by qRT-PCR analysis. In a validation set consisting of 142 serum samples 
from gastric cancer patients and 105 control serum samples, the quantification of serum 
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level of these five microRNAs could successfully separate gastric cancer cases from normal 
donors. The areas under the receiver operating characteristic (ROC) curve of this five-
microRNA signature was even markedly higher than these of widely used biomarkers such 
as serum carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9), 
indicating that expression levels of this serum miRNA-based biomarker could be potential 
biomarkers for the detection of gastric cancer (Liu et al., 2011). Other reports indicated that 
plasma level of miR-17, miR-106b, and miR-106a could also be useful for the detection of 
gastric cancer (Tsujiura et al., 2010; Zhou et al., 2010). Currently, the detection of circulating 
microRNAs has received a great deal of attention for its potential application for the early 
detection and postoperative recurrence prediction of gastric cancer. Although approaches 
based on the detection of circulating nucleic acid have been approved for the clinical 
application, microRNAs based methods are still in their infancy. The stability of microRNAs 
and the sensitivity of microRNA detection certainly make microRNAs promising 
biomarkers for cancer detection or monitoring. More clinical trials will be needed to confirm 
the values of microRNA biomarkers in screening high-risk individuals for early detection of 
gastric cancer by further invasive examinations such as gastroendoscopy.  
5. Conclusions and perspectives 
In recent years, it has become apparent that gastric cancer is resulting from the 
accumulation of both genetic and epigenetic changes. Chronic inflammation gradually 
renders inflammatory microenvironment into tumor permissive, allowing the survival and 
growth of cancer initiating cells with reprogrammed epigenetic regulatory network. As the 
major components of epigenetic regulatory network, DNA methylation and microRNA are 
deregulated in cancer initiating cells. Although the mechanisms underlying aberrant DNA 
methylation as well as dysregulated microRNA expression are largely unknown, changes in 
patterns of DNA methylation and microRNA expression are believed to contribute to the 
initiation and progression of gastric cancer by altering the expression of genes important to 
control apoptosis, cellular proliferation and differentiation. Approaches to renormalize 
methylation patterns in both global levels such as DNA methyltransferases inhibitors or 
histone deacetyltransferases inhibitors (HDACi) or targeted therapeutics have been 
developed as novel strategies to treat cancer. Despite its promising future in cancer 
prevention and intervention, the great promise of cancer epigenetics currently lies in the 
potential in diagnostics in which epigenetic biomarkers would be helpful for risk 
assessment, early detection, prognosis prediction and monitoring of treatment response as 
well as disease relapse. The quantification of DNA methylation and microRNAs in 
peripheral blood has received a great deal of attention recently. With the progress in the 
technology of genome-wide analysis such as new generation of sequencing, more and more 
epigenetic biomarkers specific to gastric cancer will be identified in the peripheral blood, 
allowing the development of epigenetic biomarker panel alone or in combination with other 
biochemical biomarkers for the detection and monitoring of gastric cancer.  
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